Company Filing History:
Years Active: 2017
Introduction
Sven Blokland is an accomplished inventor based in Delft, Netherlands. He holds a significant patent related to antigen-binding proteins that play a crucial role in immunology. His expertise and innovative contributions have the potential to advance the field of protein purification and therapeutic applications.
Latest Patents
Sven Blokland has been awarded a patent for an "Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies." This patent details a method for purifying human IgG-CH1 domain comprising molecules using an antibody that binds to an epitope found in the CH1 domain of human IgG1, human IgG2, human IgG3, and human IgG4. The invention emphasizes the framework regions of these proteins, which resemble antibodies naturally devoid of light chains, such as those found in camelids. Additionally, the patent covers nucleic acids encoding these proteins, immunoadsorbent materials containing them, and their use in purifying IgG-CH1 domain molecules from various species.
Career Highlights
Sven Blokland currently works at Bac IP B.V., where he leverages his expertise in protein engineering and purification techniques. His innovative approach has established him as a key figure in the advancements of binding protein technologies. Throughout his career, he has contributed to the development of technologies aimed at enhancing the efficacy of therapeutic proteins.
Collaborations
In his professional journey, Sven collaborates with notable coworkers including Wilhelmus Josephus Johanna Hermans and Maria Anna Van Kesteren. These relationships enhance his innovative work and contribute to fruitful research initiatives in his field.
Conclusion
Sven Blokland is a pioneering inventor whose work on antigen-binding proteins has significant implications for the purification of therapeutic antibodies. His contributions not only advance scientific knowledge but also hold promise for improving medical treatments. Through his role at Bac IP B.V., Sven continues to explore the frontiers of innovation in protein technology.